libigrow XXXTREME Capsules — Class I drug recall D-333-2013
Terminated recall by Performance Plus Marketing, Inc., reported 2013-05-22, distributed nationwide. Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of t
| Recall number | D-333-2013 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Performance Plus Marketing, Inc., Commerce, CA, United States |
| Recall initiated | 2012-12-17 |
| Classified | 2013-05-16 |
| Reported by FDA | 2013-05-22 |
| Terminated | 2013-11-14 |
| Distributed | Nationwide (US) |
| Quantity | 686,000 capsules |
| Reason classes | undeclared allergen, unapproved product |
| UPC / GTIN / UDI-DI | 00610585435922, 00610585435939, 00705105830735 |
| Lot numbers | 01/14, 01MNU0912, 01X0412-1, 021647, 04/15, 04/16, 05X0412, 09/15, 10M0111, 10X0412, 12/13 |
Product
libigrow XXXTREME Capsules, MAXIMUM STRENGTH FORMULA, 1000 mg, supplied in 1, 5 and 10 count blister packs, Distributed By Kretek International, Inc. Moorpark, CA 930210 1 count blister: UPC 705105830735, 5 count blister: UPC 610585435939, 10 count blister: UPC 610585435922.
Reason for recall
Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-333-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.